Chargement en cours...
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
BACKGROUND: The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for bleeding prevention. However, the risk of in...
Enregistré dans:
| Publié dans: | Res Pract Thromb Haemost |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7938619/ https://ncbi.nlm.nih.gov/pubmed/33733033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12475 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|